Use of a fluoropolymer-based paclitaxel-eluting stent for arteriovenous graft outflow vein stenosis in hemodialysis patients

• DOI: 10.1016/j.jvscit.2021.03.007
• Publication Date: 2021-04-21T04:10:57Z
• Authors: Yuki Matsuoka; Osamu Iida; Kotaro Suemitsu; Kanako Oka; Naomi Ota; Masaaki Izumi
• Keywords: Stenosis; Paclitaxel; RD1-811; Arteriovenous shunt; 03 medical and health sciences; 0302 clinical medicine; Hemodialysis; RC666-701; Case report; Diseases of the circulatory (Cardiovascular) system; Surgery; Drug-eluting stents

We implanted a fluoropolymer-based paclitaxel-eluting stent (FP-PES) in four hemodialysis patients with refractory outflow venous stenosis of their arteriovenous graft. The mean observation period after FP-PES implantation was 11.5 ± 4.7 months (range, 7.0-18.0 months). After FP-PES implantation, the patients were evaluated by ultrasound every 3 months. No of the patients experienced neointimal hyperplasia in the stents during the observation period, and no reintervention was performed. FP-PESs could be an attractive alternative to percutaneous transluminal angioplasty for patients with refractory outflow venous stenosis of arteriovenous hemodialysis grafts.